Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 21,600 shares, an increase of 71.4% from the May 15th total of 12,600 shares. Based on an average trading volume of 23,000 shares, the short-interest ratio is presently 0.9 days. Currently, 0.3% of the company’s stock are short sold.
Akari Therapeutics Price Performance
Shares of NASDAQ AKTX opened at $3.05 on Friday. The business has a 50 day simple moving average of $1.64 and a 200 day simple moving average of $2.23. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $5.50.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Akari Therapeutics in a research report on Tuesday. They set a “sell” rating for the company.
Institutional Trading of Akari Therapeutics
An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC grew its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX – Free Report) by 48.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 5.06% of the company’s stock.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Akari Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Dave & Buster’s Stock Offers a Prime Buying Opportunity
- There Are Different Types of Stock To Invest In
- The FOMC Decision Means Higher Prices for Stocks This Summer
- What is the Nikkei 225 index?
- Here’s Why Analysts Boosted Walmart Stock’s Valuation
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
